STUDY OBJECTIVES: To investigate the roles of human alpha-defensin (HAD), human beta-defensin (HBD)-1, and HBD-2, novel antimicrobial peptides, in patients with Mycobacterium avium-intracellulare infection (MAI). PATIENTS: The study included 25 patients (10 men) with MAI who visited our hospital between June 1998 and August 1999. MEASUREMENTS AND RESULTS: In patients with pulmonary MAI, we measured HAD and HBD-1, and HBD-2 levels in plasma and in BAL fluid (BALF) by radioimmunoassay. Plasma concentrations of HAD and HBD-2 in those patients were higher than those in control subjects, whereas HBD-1 levels were similar to those in the control subjects. High levels of HAD and HBD-2, but not HBD-1, also were observed in the BALF of MAI patients. There was a positive correlation between HAD and interleukin (IL)-8 concentrations in the BALF of patients with MAI. BALF HBD-2 concentrations also correlated positively with those of plasma HBD-2 and BALF IL-1 beta in MAI patients. Patients with cavity formation on the chest roentgenogram had higher HAD and HBD-2 levels in their BALF than those of patients without cavity formation. Treatment with clarithromycin combined with two or three other antibiotics, including ethambutol, rifampicin, ofloxacin, or ciprofloxacin, for at least 6 months resulted in a significant fall in plasma HBD-2 concentrations in responders, but not in nonresponders. CONCLUSION: Our findings suggest that HAD and HBD-2 may participate in host defense and local remodeling of the respiratory tract in patients with MAI and that plasma HBD-2 levels may be a useful marker of disease activity in patients with pulmonary MAI.
STUDY OBJECTIVES: To investigate the roles of human alpha-defensin (HAD), humanbeta-defensin (HBD)-1, and HBD-2, novel antimicrobial peptides, in patients with Mycobacterium avium-intracellulareinfection (MAI). PATIENTS: The study included 25 patients (10 men) with MAI who visited our hospital between June 1998 and August 1999. MEASUREMENTS AND RESULTS: In patients with pulmonary MAI, we measured HAD and HBD-1, and HBD-2 levels in plasma and in BAL fluid (BALF) by radioimmunoassay. Plasma concentrations of HAD and HBD-2 in those patients were higher than those in control subjects, whereas HBD-1 levels were similar to those in the control subjects. High levels of HAD and HBD-2, but not HBD-1, also were observed in the BALF of MAI patients. There was a positive correlation between HAD and interleukin (IL)-8 concentrations in the BALF of patients with MAI. BALF HBD-2 concentrations also correlated positively with those of plasma HBD-2 and BALF IL-1 beta in MAI patients. Patients with cavity formation on the chest roentgenogram had higher HAD and HBD-2 levels in their BALF than those of patients without cavity formation. Treatment with clarithromycin combined with two or three other antibiotics, including ethambutol, rifampicin, ofloxacin, or ciprofloxacin, for at least 6 months resulted in a significant fall in plasma HBD-2 concentrations in responders, but not in nonresponders. CONCLUSION: Our findings suggest that HAD and HBD-2 may participate in host defense and local remodeling of the respiratory tract in patients with MAI and that plasma HBD-2 levels may be a useful marker of disease activity in patients with pulmonary MAI.
Authors: Jenny E Han; Jessica A Alvarez; Jennifer L Jones; Vin Tangpricha; Mona A Brown; Li Hao; Lou Ann S Brown; Greg S Martin; Thomas R Ziegler Journal: Nutrition Date: 2017-02-27 Impact factor: 4.008
Authors: Bruno Rivas-Santiago; Stephan K Schwander; Carmen Sarabia; Gill Diamond; Marcia E Klein-Patel; Rogelio Hernandez-Pando; Jerrold J Ellner; Eduardo Sada Journal: Infect Immun Date: 2005-08 Impact factor: 3.441
Authors: T Hiratsuka; H Mukae; H Iiboshi; J Ashitani; K Nabeshima; T Minematsu; N Chino; T Ihi; S Kohno; M Nakazato Journal: Thorax Date: 2003-05 Impact factor: 9.139
Authors: H Mukae; H Iiboshi; M Nakazato; T Hiratsuka; M Tokojima; K Abe; J Ashitani; J Kadota; S Matsukura; S Kohno Journal: Thorax Date: 2002-07 Impact factor: 9.139
Authors: Malte Book; QiXing Chen; Lutz E Lehmann; Sven Klaschik; Stefan Weber; Jens-Christian Schewe; Markus Luepertz; Andreas Hoeft; Frank Stuber Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Ehab H Mattar; Hussein A Almehdar; Abdullah A AlJaddawi; Isam ElDin M Abu Zeid; Elrashdy M Redwan Journal: J Immunol Res Date: 2016-06-20 Impact factor: 4.818
Authors: Bruno Rivas-Santiago; Julio E Castañeda-Delgado; Cesar E Rivas Santiago; Matt Waldbrook; Irma González-Curiel; Juan C León-Contreras; Jose Antonio Enciso-Moreno; Victor del Villar; Jazmin Mendez-Ramos; Robert E W Hancock; Rogelio Hernandez-Pando Journal: PLoS One Date: 2013-03-21 Impact factor: 3.240